FDA approves new drug for chronic lymphocytic leukemia, small lymphocytic lymphoma
The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Jan 24, 2023
0
3